S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
S&P 500   3,640.47
DOW   29,225.61
QQQ   271.87
Yes, You Can Negotiate with Franchisors. Here's How.
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
A Trio of Q3 Winners With Room to Run
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
2 Casino Stocks Worth Taking a Look At
Asian stocks follow Wall St. higher after UK calms markets
Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush." (Ad)
This Small-Cap Healthcare Name Is Outperforming Its Index
What Cintas Can Teach Investors About This Bear Market?
NASDAQ:MDXG

MiMedx Group - MDXG Stock Forecast, Price & News

$2.95
-0.11 (-3.59%)
(As of 09/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.93
$3.14
50-Day Range
$2.71
$4.22
52-Week Range
$2.68
$8.69
Volume
532,796 shs
Average Volume
548,582 shs
Market Capitalization
$335.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

MiMedx Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
171.2% Upside
$8.00 Price Target
Short Interest
Bearish
3.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of MiMedx Group in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$222,266 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.33) to ($0.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

521st out of 1,097 stocks

Surgical & Medical Instruments Industry

55th out of 107 stocks

MDXG stock logo

About MiMedx Group (NASDAQ:MDXG) Stock

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MDXG Stock News Headlines

MDXG: New Product Launches
MIMEDX Announces Launch of AXIOFILL™
MIMEDX Announces Launch of AMNIOEFFECT™
MIMEDX EPIFIX® Receives Reimbursement Approval in Japan
MDXG: New Captain on the Bridge
MiMedx Group Misses Q2 EPS by 5c
MDXG: 2Q:22 Financial and Operational Results
Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?
MIMEDX Addresses Presentation by Prescience Point
See More Headlines
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MDXG Company Calendar

Last Earnings
8/02/2022
Today
9/29/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDXG
Employees
811
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+171.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,280,000.00
Pretax Margin
-8.26%

Debt

Sales & Book Value

Annual Sales
$258.61 million

Miscellaneous

Free Float
91,342,000
Market Cap
$335.15 million
Optionable
Optionable
Beta
1.75

Key Executives

  • Mr. K. Todd Newton (Age 59)
    Interim CEO & Director
    Comp: $69.5k
  • Mr. Peter Martin Carlson CPA (Age 58)
    Chief Financial Officer
    Comp: $787.81k
  • Mr. William F. Hulse IV (Age 48)
    Gen. Counsel & Chief Admin. Officer
    Comp: $733.69k
  • Dr. Rohit Kashyap Ph.D. (Age 51)
    Pres of Wound Care & Surgical
    Comp: $741.29k
  • Dr. Robert Benjamin Stein M.D. (Age 71)
    Ph.D., Pres of Regenerative Medicine & Biologics Innovation
    Comp: $731.25k
  • Mr. Scott M. Turner (Age 57)
    Sr. VP of Operations & Procurement
  • Mr. William L. Phelan
    Sr. VP & Chief Accounting Officer
  • Mr. John J. Howarth
    Sr. VP of Investor Relations
  • Mr. Mark P. Graves (Age 56)
    Sr. VP & Chief Compliance Officer
  • Hilary Dixon
    VP of Investor Relations & Corp. Strategic Communications













MDXG Stock - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings
or view top-rated stocks.

What is MiMedx Group's stock price forecast for 2022?

1 Wall Street analysts have issued 1-year price targets for MiMedx Group's stock. Their MDXG share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 171.2% from the stock's current price.
View analysts price targets for MDXG
or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2022?

MiMedx Group's stock was trading at $6.04 at the start of the year. Since then, MDXG shares have decreased by 51.2% and is now trading at $2.95.
View the best growth stocks for 2022 here
.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our MDXG earnings forecast
.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) posted its quarterly earnings results on Tuesday, August, 2nd. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The firm earned $66.88 million during the quarter, compared to the consensus estimate of $65.07 million.

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $2.95.

How much money does MiMedx Group make?

MiMedx Group (NASDAQ:MDXG) has a market capitalization of $335.15 million and generates $258.61 million in revenue each year. The company earns $-10,280,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does MiMedx Group have?

The company employs 811 workers across the globe.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The official website for the company is www.mimedx.com. The company can be reached via phone at (770) 651-9100, via email at investorrelations@mimedx.com, or via fax at 678-384-6741.

This page (NASDAQ:MDXG) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.